BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE’s management will participate in two investor conferences in March.
Details are as follows:
| TD Cowen 45th Annual Health Care Conference, Boston, MA | ||
| Conference Date: | March 4, 2025 | |
| Format: | Fireside chat and one-on-one meetings | |
| Fireside Chat Timing: | Tuesday, March 4, 2025, 11:10 AM ET | |
| Registration: | Webcast link | |
| Leerink Partners Global Healthcare Conference, Miami, FL | ||
| Conference Date: | March 11, 2025 | |
| Format: | One-on-one meetings | |
A webcast replay will be available on the VYNE website for 90 days following the event.
About VYNE Therapeutics Inc.
VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE’s unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission (“SEC”), public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@vynetx.com
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com
2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…
2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based…
From combination surgeries to advanced skin therapies, The Naderi Center outlines how patients nationwide are…
Potential Schedule III Status Could Improve Legal Clarity for Patients Traveling from Colombia to the…
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…